UNC Chapel Hill Gene Therapy Center spinout developing GENV HEM, a universal gene therapy for all types of hemophilia (including patients with inhibitors to clotting factors); pipeline expanded to include a Pompe disease program in 2025.
At a glance
- HQ: Chapel Hill
- Sector: Biotech
- Stage: Pre Seed
- Total raised: $1.4M
- Affiliation: UNC
Where the team studied
Filter the directory by schoolDuke University
- Damon RaceAlumM.B.A., BusinessSource
Each line was checked against a primary source. Founder education is recorded for part of the directory, so a name missing here is a gap in what has been checked, not a statement that they studied somewhere else. Tell me what is missing.
The rest of this record is behind a free account.
Founders, funding history, investor connections, and recent signals load on this page as soon as you sign in. Accounts open immediately, and I read every signup.